Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "lung cancer screening"

Clinical trialCLINICALTRIALSApr 28

Trial Now Recruiting: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05168566)

Researchers are testing a new drug called Sutetinib Maleate Capsule to treat advanced lung cancer in patients who have specific uncommon mutations in their cancer cells. This is a Phase 2 study, which means the drug has already been tested for safety in a small group and now researchers want to see how well it works in a larger group of about 99 patients. The study is currently accepting new participants at multiple hospitals.

WHY IT MATTERSThis trial offers access to a targeted therapy specifically designed for patients with non-small cell lung cancer carrying rare EGFR mutations (L861Q, G719X, S768I) who may have limited treatment options.
→ You can act on thisnon-small cell lung cancer
Clinical trialCLINICALTRIALSApr 24

Trial Now Recruiting: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)

Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.

WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
→ You can act on thisnon-small cell lung cancerlocally advanced non-small cell lung cancermetastatic non-small cell lung cancer
Clinical trialCLINICALTRIALSApr 24

Trial Now Recruiting: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (NCT06706076)

Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.

WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
→ You can act on thisnon-small cell lung cancer (NSCLC)locally advanced NSCLCmetastatic NSCLC

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases